ASCO 2021: Updates in Lung Cancer

ASCO 2021: Updates in Lung Cancer

Pasireotide Plus Everolimus Improves PFS in Advanced Neuroendocrine Tumors of the Lung or Thymus

Phase 2 data show a progression-free survival benefit with the combination of pasireotide and everolimus in patients with advanced neuroendocrine tumors of the lung or thymus.

Cancer Therapy Advisor
Atezolizumab Reduces Risk of Disease Progression and Death in Patients With PD-L1–Expressing Early-Stage NSCLC

Atezolizumab given after CT to patients with resected stage II to IIIA NSCLC significantly improves DFS compared with best supportive care alone in patients whose tumors expressed PD-L1.

The ASCO Post
No Survival Difference With Once-Daily vs Twice-Daily Radiotherapy in Small Cell Lung Cancer

Once-daily, high-dose thoracic radiotherapy does not significantly improve survival compared with lower-dose, twice-daily TRT for LSCLC, according to phase 3 trial results from the 2021 ASCO Annual

Cancer Therapy Advisor

Urine Metabolites Could Predict End of Life in Lung Cancer

Lung cancer patients could soon have their risk of dying over the following 3 months accurately predicted by analyzing their urine samples, allowing them to better prepare for their end of life...<

Less Pain, Fewer Complications With VATS vs Open Surgery in Early-Stage Lung Cancer

Video-assisted thoracoscopic surgery is associated with better physical function, less pain, and fewer complications, compared with open surgery, in patients with early-stage lung cancer.

Cancer Therapy Advisor
Nasal Swab Test Helps Identify Malignant Lung Nodules

A simple nasal swab may help in the diagnosis of lung cancer in smokers who have undergone CT screening and had lung nodules detected on the scan.  

G1 Therapeutics Presents Data on trilaciclib at ASCO on Potential Immune Activation in Newly Diagnosed Extensive-Stage SCLC

G1 Therapeutics today presented results from analyses evaluating the immune effects of trilaciclib in patients with extensive-stage SCLC at the ASCO Annual Meeting.

Pivotal Phase III Data at ASCO Show Genentech’s Tecentriq Helps Certain People With Early Lung Cancer Live Significantly Longer Without Their Disease Returning

Genentech today announced interim results from the phase III IMpower010 study, showing for the first time that atezolizumab following surgery and chemo reduced the risk of disease recurrence or dea

ASCO 2021: Watch for Sanofi/Sloan Kettering, Incyte, Exelixis and AstraZeneca

The ASCO Annual Meeting will be held virtually from June 4 to 8, 2021.

News from ASCO: Chemotherapy-Free Regimens in NSCLC and CLL

Data on durable efficacy of two investigational chemotherapy-free treatments for non-small cell lung cancer (NSCLC) or chronic lymphocytic leukemia (CLL) will be presented at the upcoming American

Brigatinib Safe, Effective for Crizotinib-Refractory ALK+ NSCLC

According to study data being presented by Scott N.

Oncology Learning Network

source list reference

rgb(171, 222, 222)
rgb(219, 18, 118)
200, 66, 245
rgb(195, 2, 230)
rgb (247, 7, 79)
rgb(14, 133, 237)
rgb(252, 3, 223)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(252, 186, 3)
rgb(242, 0, 137)
rgb (247, 7, 79)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb (252, 186, 3)
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
rgb(224, 4, 129)
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
rgb (245, 152, 2)
rgb(169, 196, 201)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb (191, 171, 145)
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
rbg(16, 162, 230)
rgb(217, 7, 192)
rgb(224, 224, 4)
rgb(2, 230, 230)
rgb(186, 130, 237)
rgb(235, 64, 52)